Christian H.K. Lehmann
YOU?
Author Swipe
View article: Multi-Epitope DC Vaccines with Melanoma Antigens for Immunotherapy of Melanoma
Multi-Epitope DC Vaccines with Melanoma Antigens for Immunotherapy of Melanoma Open
Background/Objectives: The revolution for the treatment of melanoma came with the approval of checkpoint blockade antibodies. However, a substantial proportion of patients show primary or secondary resistance to this type of immunotherapy,…
View article: A Half-Century of Heterotopic Heart Transplantation in Mice: The Spearhead of Immunology Research
A Half-Century of Heterotopic Heart Transplantation in Mice: The Spearhead of Immunology Research Open
Since the success of solid organ transplants, such as human kidneys, livers and hearts, from the 50s to the 60s in the last century, the field of organ transplantation has progressed rapidly. Mainly due to modifications in surgical operati…
View article: Protocol for mapping the heterogeneous dendritic cell network across the murine tissue landscape via high-dimensional flow cytometry
Protocol for mapping the heterogeneous dendritic cell network across the murine tissue landscape via high-dimensional flow cytometry Open
View article: Pharmacodynamic Effect of mTOR Inhibition-based Immunosuppressive Therapy on T- and B-cell Subsets After Renal Transplantation
Pharmacodynamic Effect of mTOR Inhibition-based Immunosuppressive Therapy on T- and B-cell Subsets After Renal Transplantation Open
Background. The mammalian target of rapamycin inhibitor (mTORi) therapy after kidney transplantation is solely monitored pharmacokinetically, not necessarily reflecting PI3K-Akt-mTOR pathway blockade efficacy leading to potential under-or …
View article: Clec12A, CD301b, and FcγRIIB/III define the heterogeneity of murine DC2s and DC3s
Clec12A, CD301b, and FcγRIIB/III define the heterogeneity of murine DC2s and DC3s Open
Over the last decade, multiple studies have investigated the heterogeneity of murine conventional dendritic cells type 2 (cDC2s). However, their phenotypic similarity with monocytes and macrophages renders their clear identification challe…
View article: Supplementary Table S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S3 contains the list of genes that are significantly upregulated by both BCL2 inhibitor and Bcl2 knockout, as well as their link to the Type 1 IFN responses
View article: Supplementary Figure S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S2 contains data suggesting the activation of the dsDNA/cGAS/STING/Type IFN pathway by BCL2 inhibition.
View article: Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S3 shows the increased DC maturation and activation upon BCL2 inhibition, and indicates that this effect is crucial for the enhancement of DC antigen cross presentation by BCL2 inhibitors.
View article: Supplementary Figure S5 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S5 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S5 contains evidence indicating that BCL2 inhibitors synergize with immune checkpoint blockades in different mouse orthotopic cancer models.
View article: Supplementary Figure S8 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S8 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S8 shows T cell-priming by adoptively transferred cDC1 cells, their T-cell dependent cancer-regressing effect, as well as sensitization to PD-1 blockade.
View article: Supplementary Table S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S2 contains the full list of genes involved in the arrayed CRISPR screening and the top candidate genes detected by this screening, as well as their link to seven potentially druggable pathways.
View article: Supplementary Table S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S1 contains the full list of genes involved in the pooled CRISPR screening and the top candidate genes selected from this screening.
View article: Supplementary Figure S6 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S6 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S6 demonstrates the specific activation of the Type I conventional DC (cDC1) subset by BCL2 inhibitors in different mouse orthotopic cancer models.
View article: Supplementary Figure S9 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S9 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S9 shows the migration arrest of cDC1 by CD11b blocking antibody, as well as the effects of T cell depletion or CD11b blockade on BCL2 inhibitor-mediated control of fibrosarcomas.
View article: Supplementary Figure S7 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S7 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S7 shows the activation of human peripheral cDC1 cells by BCL2 inhibitors, as well as the in vivo migration of adoptively transferred cDC1 cells that were either WT, BCL2 inhibitor-treated or Bcl2 knock out.
View article: Supplementary Figure S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S2 contains data suggesting the activation of the dsDNA/cGAS/STING/Type IFN pathway by BCL2 inhibition.
View article: Supplementary Figure S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S1 lists pathways that connect candidate genes selected form the array CRISPR screening and the potential mechanisms for DC antigen cross-presentation enhancement by BCL2 inhibition including apoptosis and autophagy.
View article: Supplementary Table Legends from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table Legends from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
This file contains full legends to all supplmentary tables.
View article: Supplementary Figure S5 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S5 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S5 contains evidence indicating that BCL2 inhibitors synergize with immune checkpoint blockades in different mouse orthotopic cancer models.
View article: Supplementary Table S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S4 contains the sequences of all qPCR primers used in this study.
View article: Supplementary Table S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S1 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S1 contains the full list of genes involved in the pooled CRISPR screening and the top candidate genes selected from this screening.
View article: Supplementary Table S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S2 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S2 contains the full list of genes involved in the arrayed CRISPR screening and the top candidate genes detected by this screening, as well as their link to seven potentially druggable pathways.
View article: Supplementary Figure S7 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S7 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S7 shows the activation of human peripheral cDC1 cells by BCL2 inhibitors, as well as the in vivo migration of adoptively transferred cDC1 cells that were either WT, BCL2 inhibitor-treated or Bcl2 knock out.
View article: Supplementary Figure S8 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S8 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S8 shows T cell-priming by adoptively transferred cDC1 cells, their T-cell dependent cancer-regressing effect, as well as sensitization to PD-1 blockade.
View article: Supplementary Figure S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S4 shows the weak cancer cell apoptosis triggered by BCL2 inhibitors, and the increased expression of immune checkpoint markers on T cells from BCL2 inhibitor-treated cancer-bearing mice.
View article: Supplementary Table S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Table S3 contains the list of genes that are significantly upregulated by both BCL2 inhibitor and Bcl2 knockout, as well as their link to the Type 1 IFN responses
View article: Supplementary Table Legends from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Table Legends from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
This file contains full legends to all supplmentary tables.
View article: Data from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Data from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
We developed a phenotypic screening platform for the functional exploration of dendritic cells (DC). Here, we report a genome-wide CRISPR screen that revealed BCL2 as an endogenous inhibitor of DC function. Knockout of BCL2 enhanced DC ant…
View article: Supplementary Figure S10 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S10 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S10 shows selective cDC1 depletion by cytochrome c injections, as well as the effects of cDC1 depletion on BCL2 inhibitor-induced T cell activation and fibrosarcoma control.
View article: Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance Open
Supplementary Figure S3 shows the increased DC maturation and activation upon BCL2 inhibition, and indicates that this effect is crucial for the enhancement of DC antigen cross presentation by BCL2 inhibitors.